QuidelOrtho announced today that it terminated President and CEO Douglas Bryant, effective immediately.

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023.

Becton Dickinson announced on Wednesday that it has partnered with digital health firm Camtech Health to increase cervical cancer screening in Singapore through self-collection of samples.

From 1 January to 31 December 2023, China’s NMPA accepted a total of 13,260 applications for the first registration, renewal of registration and change of registration of medical devices in accordance with its duties, an increase of 25.4% compared with 2022.

A new UK industry body designed to help medical device regulators navigate the new legal landscape of a post-Brexit Britain has launched with backing from 11 companies.

The US Food and Drug Administration on Tuesday issued a letter to medical device manufacturers and sponsors of device studies warning them to independently verify performance test results before submitting them to the agency due to concerns about fraudulent results.

If Chinese chemiluminescence would eventually replace imported products completely, it must ensure the accuracy and reliability of the test results. In addition to the improvement of equipment system and methodology, the accuracy of results will involve two very core competitions in the future.

Freenome said on Thursday that it raised $254 million in funding from existing and new investors to advance its pipeline of single- and multi-cancer early detection tests.

Werfen has received CE marking for its Aptiva antiphospholipid syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents, meaning the in vitro diagnostics can now be used in the EU.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023.

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 31, 2023.

The analyzer will develop in two directions as per different customer needs and application scenarios.

SCIEX, a global leader in life science analytical technologies, launches the Echo® MS+ system at SLAS 2024. The system couples proprietary Acoustic Ejection Mass Spectrometry technology and Open Port Interface (OPI) sampling with the capabilities of either the SCIEX ZenoTOF 7600 or Triple Quad 6500+ system to deliver precise qualitative and quantitative results, through an expanded panel of robust high-throughput screening workflows.